Trade Neurocrine Biosciences, Inc. - NBIX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.29 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.7 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 146.16 |
| Open | 143.57 |
| 1-Year Change | 42.19% |
| Day's Range | 143.57 - 147.78 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 145.94 | 0.43 | 0.30% | 145.51 | 148.40 | 144.75 |
| Jul 24, 2024 | 145.28 | 1.34 | 0.93% | 143.94 | 146.63 | 143.35 |
| Jul 23, 2024 | 145.19 | 1.30 | 0.90% | 143.89 | 146.30 | 143.76 |
| Jul 22, 2024 | 144.70 | -0.92 | -0.63% | 145.62 | 148.11 | 144.54 |
| Jul 19, 2024 | 145.63 | 1.23 | 0.85% | 144.40 | 146.10 | 142.89 |
| Jul 18, 2024 | 144.01 | -0.71 | -0.49% | 144.72 | 147.82 | 143.67 |
| Jul 17, 2024 | 144.13 | -1.88 | -1.29% | 146.01 | 147.92 | 143.29 |
| Jul 16, 2024 | 147.28 | 0.38 | 0.26% | 146.90 | 149.88 | 146.88 |
| Jul 15, 2024 | 147.27 | 0.41 | 0.28% | 146.86 | 149.25 | 144.87 |
| Jul 12, 2024 | 147.24 | 1.76 | 1.21% | 145.48 | 148.86 | 145.48 |
| Jul 11, 2024 | 146.33 | -0.21 | -0.14% | 146.54 | 148.43 | 145.70 |
| Jul 10, 2024 | 147.01 | 4.25 | 2.98% | 142.76 | 147.45 | 142.51 |
| Jul 9, 2024 | 143.20 | 2.38 | 1.69% | 140.82 | 143.22 | 138.72 |
| Jul 8, 2024 | 142.18 | 3.60 | 2.60% | 138.58 | 142.28 | 138.58 |
| Jul 5, 2024 | 138.91 | 1.76 | 1.28% | 137.15 | 139.53 | 135.43 |
| Jul 3, 2024 | 137.80 | 0.93 | 0.68% | 136.87 | 138.67 | 136.81 |
| Jul 2, 2024 | 137.31 | -0.60 | -0.44% | 137.91 | 138.91 | 136.57 |
| Jul 1, 2024 | 139.94 | 2.59 | 1.89% | 137.35 | 140.99 | 136.20 |
| Jun 28, 2024 | 137.47 | 3.15 | 2.35% | 134.32 | 139.08 | 134.32 |
| Jun 27, 2024 | 133.72 | -1.95 | -1.44% | 135.67 | 136.40 | 133.46 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Neurocrine Company profile
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Neurocrine Biosciences, Inc. revenues increased 8% to $1.13B. Net income decreased 78% to $89.6M. Revenues reflect Net product sales increase of 10% to $1.09B. Net income was offset by General and administrative -others increase of 36% to $497.5M (expense), Research and development - others increase of 16% to $279.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 110M auth. 55,200,641 issd. Insiders own 1.73%. IPO: 5/96, 4,394,286 shares (1,214,286 by the Company) @ $10.50 by Robertson, Stephens & Co. LLC. PO: 12/00, 3M shares @ $30 by Robertson Stephens. PO 12/01, 3.5M shares @ $46.75 by Deutsche Banc Alex. Brown. FY'00 Q's are restated.
| Industry: | Bio Therapeutic Drugs |
12780 El Camino Real
SAN DIEGO
CALIFORNIA 92130-2042
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com